Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non- CRLF2 -Rearranged JAK Pathway Alterations

Sarah K Tasian, Deborah S Hunter, I-Ming L Chen, Richard C Harvey, Andrew J. Carroll, Elizabeth Wagner, Shalini C Reshmi, Michael J Borowitz, Brent L. Wood, Jeannie Daniel, Meenakshi Devidas, Elizabeth A. Raetz, Stephen P. Hunger, Albert Assad, Mignon L. Loh

Blood (2022) 140 (Supplement 1): 6117–6118.

https://doi.org/10.1182/blood-2022-164699

Published: 2022

Journal Articles

A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (INCB18424-269/AALL1521): Dose-Finding Results from the Part 1 Safety Phase

Sarah K. Tasian, MD, Albert Assad, MD, Deborah S Hunter, PhD, Yining Du, PhD, Mignon L. Loh, MD

Blood (2018) 132 (Supplement 1): 555.

https://doi.org/10.1182/blood-2018-99-110221

Published: 2018

Journal Articles

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

Francisco Cervantes, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Andres Sirulnik, Viktoriya Stalbovskaya, Mari McQuitty, Deborah S. Hunter, Richard S. Levy, Francesco Passamonti, Tiziano Barbui, Giovanni Barosi, Claire N. Harrison, Laurent Knoops, Heinz Gisslinger

Blood (2013) 122 (25): 4047–4053.

https://doi.org/10.1182/blood-2013-02-485888

Published: 2013

Includes: Supplemental data

Journal Articles

Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF)

Francisco Cervantes, MD, Jean-Jacques Kiladjian, MD, PhD, Dietger Niederwieser, Andres Sirulnik, MD, PhD, Viktoriya Stalbovskaya, PhD, Mari McQuity, RN, MPH, Deborah S. Hunter, PhD, Richard S. Levy, MD, Francesco Passamonti, MD, Tiziano Barbui, MD, Giovanni Barosi, MD, Heinz Gisslinger, MD, Alessandro M. Vannucchi, MD, Laurent Knoops, MD, PhD, Claire N Harrison, DM FRCP FRCPath

Blood (2012) 120 (21): 801.

https://doi.org/10.1182/blood.V120.21.801.801

Published: 2012

Journal Articles

Health-Related Quality of Life and Symptoms in Myelofibrosis Patients Treated with Ruxolitinib Versus Best Available Therapy

Claire N. Harrison, DM, FRCP, FRCPath, Jean-Jacques Kiladjian, MD, PhD, Haifa Kathrin Al-Ali, MD, Heinz Gisslinger, MD, Laurent Knoops, MD, PhD, Roger J. Waltzman, MD, Estella T. Mendelson, BSRN, MBA, Xiaolei Zhou, Catherine Copley-Merriman, Deborah S. Hunter, PhD, Richard S. Levy, MD, Francisco Cervantes, MD, PhD, Francesco Passamonti, MD, Alessandro M. Vannucchi, MD, Tiziano Barbui, MD, Giovanni Barosi, MD

Blood (2011) 118 (21): 795.

https://doi.org/10.1182/blood.V118.21.795.795

Published: 2011

Journal Articles

Ruxolitinib Provides Reductions in Splenomegaly Across Subgroups: An Analysis of Spleen Response in the COMFORT-II Study

Claire N. Harrison, DM, FRCP, FRCPath, Jean-Jacques Kiladjian, MD, PhD, Heinz Gisslinger, MD, Dietger Niederwieser, MD, Francesco Passamonti, MD, Roger J. Waltzman, MD, Norbert Hollaender, PhD, Deborah S. Hunter, PhD, Richard S. Levy, MD, Laurent Knoops, MD, PhD, Francisco Cervantes, MD, PhD, Alessandro M. Vannucchi, MD, Tiziano Barbui, MD, Giovanni Barosi, MD

Blood (2011) 118 (21): 279.

https://doi.org/10.1182/blood.V118.21.279.279

Published: 2011

NARROW

A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non- CRLF2 -Rearranged JAK Pathway Alterations

A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (INCB18424-269/AALL1521): Dose-Finding Results from the Part 1 Safety Phase

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF)

Health-Related Quality of Life and Symptoms in Myelofibrosis Patients Treated with Ruxolitinib Versus Best Available Therapy

Ruxolitinib Provides Reductions in Splenomegaly Across Subgroups: An Analysis of Spleen Response in the COMFORT-II Study

Email alerts

ASH Publications

American Society of Hematology

A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non- CRLF2 -Rearranged JAK Pathway Alterations

A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (INCB18424-269/AALL1521): Dose-Finding Results from the Part 1 Safety Phase

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF)

Health-Related Quality of Life and Symptoms in Myelofibrosis Patients Treated with Ruxolitinib Versus Best Available Therapy

Ruxolitinib Provides Reductions in Splenomegaly Across Subgroups: An Analysis of Spleen Response in the COMFORT-II Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only